Journal of Community Hospital Internal Medicine Perspectives · 2018 · 27 citations · 11 references
MedicineNeurologyOncologyChemotherapyMetastasisNeuro-oncologyAngiogenesisAngiogenesis In CancerBrain MetastasesBrain MetastasisBrain TumorsMetastatic Brain TumorsBlood-brain Barrier PermeabilityImmunosuppressive Drug TherapyMonoclonal Antibody InfusionRecurrent Colorectal CancerVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitorsWhite Matter Lesions
Posterior reversible encephalopathy syndrome (PRES) is an increasingly recognizable neuro-clinical syndrome. Clinical and neurological manifestations of PRES include hypertension, headache, encephalopathy, seizures, and symmetrical white matter changes on brain MRI. Most common precipitants of PRES are acute medical illness, hypertensive crisis, eclampsia, immunosuppressive therapy, and chemotherapy. Bevacizumab is a monoclonal antibody that halts angiogenesis by inhibiting vascular endothelial growth factor. It has gained widespread popularity in oncology world especially for metastatic and recurrent cancers due to its inherent ability to stop angiogenesis; a vital step for tumor growth. Bevacizumab has also been implicated as the cause of PRES due to dysregulation of the blood-brain barrier. We are reporting a case of PRES induced by Bevacizumab in a patient of colorectal cancer.
11
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
Paul A. James, Suzanne Oparil, Barry L. Carter et al. · JAMA · 2013 · 8K citations
A Reversible Posterior Leukoencephalopathy Syndrome
Judy Hinchey, Claudia Chaves, B A Appignani et al. · New England Journal of Medicine · 1996 · 3.3K citations
Luc G.T. Morris, Andrew G. Sikora, Snehal G. Patel et al. · Journal of Clinical Oncology · 2010 · 356 citations · Full text
Medicine, Oncology, Cancer Control +16